Navigation Links
The Rottenstein Law Group LLP Notes Lifelong Side Effects of DES Can Lead to Cancer
Date:5/31/2013

(PRWEB) May 31, 2013

Diethylstilbestrol (DES), a synthetic hormone previously manufactured by several companies and formerly prescribed to pregnant women to prevent miscarriages and premature births, could potentially cause cancer in those women’s children. The Rottenstein Law Group LLP acknowledges a Centers for Disease Control report of the struggles of "DES Daughters" with a series of life-threatening cancers related to their mother’s use of the drug while pregnant. The firm maintains a DES Cancer Lawsuit Center at http://www.descancerlawsuit.com that features more details about lawsuits and the side effects of the drug.

The CDC report* notes ongoing research into the manifestation of "clear cell adenocarcinoma, structural abnormalities in the reproductive organs, infertility and pregnancy complications."

Rottenstein Law Group LLP Principal Rochelle Rottenstein comments on the research and how it relates to the communication she has received from those looking to file DES lawsuits.

“The first DES cancer lawsuits began as far back as the 1970s, but recently there have been more suits filed because of the drug’s serious alleged lifelong side effects,” Rottenstein said. “Some side effects don’t show up until later in the lives of so-called DES children and grandchildren.”

DES was prescribed to more than 10 million women from the 1940s to the 1970s to prevent miscarriages and premature births. Use of the drug by pregnant mothers allegedly led to their children experiencing cancer, infertility, and pregnancy difficulties, according to the National Cancer Institute.**

In 2013 about 51 women have filed suits in Boston against a dozen manufacturers or marketers of the drug, according to the Associated Press.*** One lawsuit was settled in January 2013 after a day at trial (1:11-cv-10152-MBB in the U.S. District Court for the District of Massachusetts).

The Rottenstein Law Group LLP encourages those who believe they have suffered DES side effects to visit its page dedicated to providing information about the DES link to certain types of cancers reportedly related to a pregnant woman’s use of the drug.

*cdc.gov/des/consumers/about/concerns_daughters.html
**cancer.gov/cancertopics/factsheet/Risk/DES
***sentinelandenterprise.com/breakingnews/ci_22341598/ap-settlement-reached-mass-lawsuit-pregnancy-drug (January 2013)

For the latest news on defective medications and medical devices and related lawsuits, visit the Rottenstein Law Group LLP’s Injury Lawyer Newswire at injurylawyernewswire.com. Readers can subscribe to the news site’s stories and videos to stay on top of personal injury news.

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

                            ###

Read the full story at http://www.prweb.com/releases/des-lawsuit/des-cancer/prweb10786743.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. FDA Says Metal-on-Metal Hip Replacements Can Cause Soft-Tissue Damage, Rottenstein Law Group Reports
2. Stryker Hip Replacement Lawsuit News: Mass. Woman Files First Known Federal Stryker ABG II Hip Lawsuit, Rottenstein Law Group Reports
3. DePuy ASR Lawsuit Update: Rottenstein Law Group Addresses J&J Motion to Appeal $8.3 Million Verdict
4. Fosamax Lawsuits Update: Rottenstein Law Group Responds to Femur Fracture Verdict in Merck’s Favor
5. Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group Comments on Testimony in Ongoing Robot Trial
6. Rottenstein Law Group Notes Medical Journal Article Advising Doctors To Use Caution When Prescribing Zithromax and Other Antibiotics
7. NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims
8. Lipitor Lawsuit News: Rottenstein Law Group Comments on FDA Approval of New Drug With Lipitor Compound
9. DePuy ASR Lawsuit Update: Rottenstein Law Group Comments on Delay of Second Federal Trial
10. Lipitor Lawsuit News: US Spending on Drugs Fell For First Time in 2012, Notes Rottenstein Law Group LLP
11. Da Vinci Surgical Robot Lawsuit News: Robot Maker Says Device Could Cause Internal Burns, Notes Rottenstein Law Group LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology: